Hemostemix Announces Submission of Orphan Drug Designation Application to the FDA
04 févr. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing...